Dose-Response Study of Phenylephrine for Preventing Spinal-Induced Hypotension During Cesarean Delivery with Combined Spinal-Epidural Anesthesia Under the Effect of Prophylactic Intravenous Ondansetron
Xiao-Xia Sun,Jing Qian,Jia-Ming Fan,Lin Liu,Xia-Fang Jin,Fei Xiao
DOI: https://doi.org/10.2147/dddt.s452983
IF: 4.3188
2024-05-01
Drug Design Development and Therapy
Abstract:Xiao-Xia Sun, Jing Qian, Jia-Ming Fan, Lin Liu, Xia-Fang Jin, Fei Xiao Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing City, People's Republic of China Correspondence: Xia-Fang Jin; Fei Xiao, Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing City, People's Republic of China, Tel +86573-83963131, Email ; Background: Ondansetron reduces the median effective dose (ED50) of prophylactic phenylephrine to prevent spinal-induced hypotension (SIH) during cesarean delivery. However, the exact dose response of phenylephrine in combination with prophylactic ondansetron for preventing SIH is unknown. Therefore, this study aimed to determine the dose-response of phenylephrine to prevent SIH in cesarean delivery when 4 mg of ondansetron was used as a preventive method. Methods: A total of 80 parturients were enrolled and divided randomly into four groups (n = 20 in each group) who received either 0.2, 0.3, 0.4, or 0.5 μg/kg/min of prophylactic phenylephrine. Ten minutes before the initiation of spinal induction, 4 mg prophylactic ondansetron was administered. The effective dose of prophylactic phenylephrine was defined as the dose required to prevent hypotension after the period of intrathecal injection and up to neonatal delivery. The ED50 and ED90 of prophylactic phenylephrine and 95% confidence intervals (95% CI) were calculated using probit analysis. Results: The ED50 and ED90 for prophylactic phenylephrine to prevent SIH were 0.25 (95% CI, 0.15 to 0.30), and 0.45 (95% CI, 0.39 to 0.59) μg/kg/min, respectively. No significant differences were observed in the side effects and neonatal outcomes between the four groups. Conclusion: The administration of 4 mg of prophylactic ondansetron was associated with an ED50 of 0.25 (95% CI, 0.15~0.30) and ED90 of 0.45 (95% CI, 0.39~0.59) μg/kg/min for phenylephrine to prevent SIH. Keywords: phenylephrine, ondansetron, dose-response, hypotension, cesarean delivery, spinal Phenylephrine infusion is an important therapeutic strategy for preventing spinal-induced hypotension (SIH) in cesarean delivery, as it decreases the incidence of hypotension, nausea and vomiting. 1–3 However, infusion high dose of phenylephrine may also result in a reduction in maternal heart rate and subsequently decrease cardiac output in a dose-dependent manner. 4–6 Our previous study showed that prophylactic ondansetron decreased the median effective dose of phenylephrine to prevent SIH, as evaluated by the median effective dose (ED50). 7,8 In theory, a potential clinical benefit may arise from a reduction in the required dosage of phenylephrine through prophylactic administration of ondansetron, as it may inhibit the Bezold-Jarisch reflex by antagonizing the binding of 5-HT3 to receptors in the left ventricle, and subsequently reduce the incidence of SIH. 9,10 However, data on the exact dose–response curve of prophylactic phenylephrine for preventing SIH administered in combination with ondansetron is still unavailable. Since many anesthesiologists prefer to administer phenylephrine at rates closer to the ED90 or ED95, the calculation of 90% or 95% effective doses are more clinically advantageous for the management of SIH than of the ED50. Therefore, this study aimed to determine the dose-response of phenylephrine for preventing SIH when prophylactic intravenous ondansetron was administered 10 min prior to combined spinal-epidural anesthesia during cesarean delivery. This study was approved by the Institutional Review Board of Jiaxing University Affiliated Women and Children's Hospital's Institutional Review Board (IRB 2019–119, date of approval: Nov 6. 2019). The clinical trial was registered at the Chinese Clinical Trials Registry Center (the registration number: ChiCTR2100042453; principal investigator, Xiao-Xia Sun) before enrollment of the parturients. All the patients signed an informed consent form. Patient recruitment was initiated on January 30, 2021, and concluded on August 30, 2021. The inclusion criteria were a singleton pregnancy at term (≥37 weeks' gestation) and American Society of Anesthesiologists (ASA) physical status of < III, for subjects undergoing elective cesarean delivery. The exclusion criteria were as follows: preeclampsia or preexisting hypertension, preexisting or gestational diabetes, allergy to phenylephrine and local anesthetics, any contraindications to spinal or epidural anesthesia, including a bleeding disorder, local infection or intracranial hypertension, cardiovascular or cerebrovascular disease, ruptured membranes and placenta previa, multiple pregnancies, height 175 cm, body weight 90 kg, and a fetal anomaly. The patients wer -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal